Systemic steroids in COPD-the beauty and the beast by Claus F Vogelmeier
Vogelmeier Respiratory Research 2014, 15:38
http://respiratory-research.com/content/15/1/38COMMENTARY Open AccessSystemic steroids in COPD-the beauty and the beast
Claus F Vogelmeier1,2The recommendations regarding the use of systemic ste-
roids in COPD differ substantially depending on the
phase of the disease. In moderate and severe acute exac-
erbations oral steroids are advocated based on the find-
ings of several placebo-controlled trials that have been
performed in secondary-care settings: these studies
showed that systemic steroids improve lung function,
dyspnoea and gas exchange. In addition, steroid use re-
sulted in fewer treatment failures, a lower relapse rate
and shorter hospital stays [1-4]. Importantly, giving ste-
roids orally is non-inferior to the i.v. application [5] and
an 8-week treatment is not superior to a 2-week therapy
[6]. Recently, it could even be shown that 5-day treat-
ment is non-inferior to a 14-day course [7]. In the trial
with longer term therapy [6] hyperglycemia requiring
treatment was identified as considerable side effect, in
the other trials no major adverse events were observed.
In contrast, in stable COPD positive effects of systemic
steroids are scarce: there is some evidence that higher
doses (≥ 30 mg prednisolone/day) may improve lung
function over a short period, whereas this was not ob-
served in doses of less than 10–15 mg prednisolone/day
[8]. In a 2-year trial with 5 mg prednisolone + 1600 μg
budesonide/day efficacy regarding lung function decline
was not significantly better than budesonide alone [9].
In addition, there are substantial side effect problems. In
particular, it is well established that respiratory and per-
ipheral muscle strength [10] are affected. This is caused
by a myopathy that is characterized by atrophy and ne-
crosis [11] and may lead to reduced survival. Besides,
there is evidence that chronic therapy with systemic ste-
roids is one of the risk factors for the high rate of osteo-
porosis that is observed in COPD [12].
What does the paper by Horita et al. published in this
issue of the journal [13] add to the literature? To my
knowledge this is the first analysis that systematically
evaluates the effects of systemic steroids on mortality inCorrespondence: Claus.Vogelmeier@med.uni-marburg.de
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very severe COPD. The authors analyzed patients (N =
444) that had been randomized to the conservative treat-
ment arm in the National Emphysema Treatment trial
(NETT). They calculated a hazard ratio for death of 1.54
for the steroid user group. Then, in order to make sure
that this result was not induced by unidentified con-
founders they performed a propensity score matching.
Based on this analysis the hazard ratio for death in the
steroid group was 1.73. Thus, the observed effect seems
to be robust and real.
Nevertheless, the authors righteously mention several
potential weaknesses of their study: a) it is not prospect-
ive, but a prospective trial with this endpoint does not
seem feasible, b) the steroid dose was not verified, c)
only patients with an FEV1 ≤ 45% predicted had been in-
cluded in the NETT trial, but logic tells that systemic
steroids should only be considered when all other ther-
apies are not sufficiently effective and it is quite unlikely
that this occurs in patients with a moderate lung func-
tion impairment. It is quite worrisome though that in
the NETT trial only a minority of the patients were
treated with long acting bronchodilators.
In summary, the study results support the recommen-
dations in guidelines and strategy documents to stay
away from the chronic use of systemic steroids in COPD
[14]. As a consequence, in patients in stable condition
that are currently treated with systemic steroids this
therapy should be tapered/stopped. This can be quite
demanding: patients may develop fatigue, low blood
pressure, joint pain, weakness and even psychotic symp-
toms [15]. Importantly, discontinuation of chronic sys-
temic steroid therapy did not result in an increase of
COPD exacerbations [16]. There is only one scenario
where steroid cessation may be harmful: some patients
with an asthma-COPD overlap may profit from long-
term use of systemic steroids [17] and may get worse
when steroids are stopped.
Based on the cited literature and supported by the
findings of Horita et al. [13] there are some simple mes-
sages regarding the use of systemic steroids in COPD: a)
in moderate or severe acute exacerbations oral steroidstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Vogelmeier Respiratory Research 2014, 15:38 Page 2 of 2
http://respiratory-research.com/content/15/1/38should be prescribed in a moderate dose (40 mg pred-
nisolone) for 5 days, b) there is no place for systemic ste-
roids in stable phase COPD, c) in patients treated with
systemic steroids outside of an exacerbation steroid
treatment should be withdrawn, d) before doing so ther-
apy should be optimized and patients should be re-
evaluated to make sure that they do not have an asthma-
COPD overlap.
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